Related Experiment Video
Updated: Jun 8, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
A case of methamphetamine use disorder treated with the antibiotic drug minocycline
Yuko Tanibuchi1, Minoru Shimagami, Goro Fukami
1Department of Psychiatry, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan. aguadebeber11@yahoo.co.jp
Abstract:
Methamphetamine (METH) use is one of the major public health concerns worldwide. Long-term use of METH induces not only dependence but also psychosis which is associated with METH-induced brain damage, including neuroinflammation produced by activated microglia. We report the case of a female patient whose psychotic symptoms in METH use disorder were successfully improved by anti-inflammatory drug minocycline therapy. Although the precise mechanism(s) underlying the efficacy of minocycline in METH use disorder are currently unclear, minocycline appears to be a good candidate for future investigation clinical trials for medication development in METH using populations.
Insights
Methamphetamine use disorder can cause psychosis and brain damage. Minocycline, an anti-inflammatory drug, successfully improved psychotic symptoms in a patient with methamphetamine use disorder, suggesting potential for future clinical trials.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Methamphetamine (METH) use disorder is a global public health issue.
- Long-term METH use is linked to dependence, psychosis, and neuroinflammation via activated microglia.
- Neuroinflammation plays a role in METH-induced brain damage and associated psychotic symptoms.
Observation:
- A case study of a female patient with METH use disorder experiencing psychotic symptoms is presented.
- The patient received treatment with the anti-inflammatory drug minocycline.
- Significant improvement in psychotic symptoms was observed following minocycline therapy.
Findings:
- Minocycline therapy demonstrated efficacy in alleviating psychotic symptoms in a patient with METH use disorder.
- The study highlights a potential therapeutic benefit of minocycline for METH-induced psychosis.
- While mechanisms are unclear, minocycline's anti-inflammatory properties may contribute to its effectiveness.
Implications:
- Minocycline shows promise as a potential therapeutic agent for METH use disorder, specifically for managing psychotic symptoms.
- Further clinical trials are warranted to investigate minocycline's efficacy and safety in larger populations with METH use disorder.
- This case suggests a novel avenue for medication development targeting neuroinflammation in substance use disorders.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Therapeutic Drug Monitoring: Affecting Factors
Rocky Mountain Spotted Fever
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Drug Abuse and Addiction: Pharmacological Phenomena
Cryptococcal Meningitis
